Holding: A generic drug manufacturer may employ the counterclaim provision of
the Hatch-Waxman Act to force correction of a use code that inaccurately ...
Aug 26, 2015 ... Case opinion for US 6th Circuit CALLOWAY v. CARACO PHARMACEUTICAL
LABORATORIES LTD. Read the Court's full decision on ...
Apr 1, 2008 ... In Caraco Pharmaceutical Laboratories, Ltd. v. Forest Laboratories, Inc., No. 07-
1404 (Fed. Cir. Apr. 1, 2008), the Federal Circuit reversed the ...
Apr 17, 2012 ... But before the FDA could approve Caraco's ANDA, Novo changed its ...
overlapped with Novo's use code, the FDA would not permit Caraco.
Dec 5, 2011 ... Novo Nordisk sued Caraco Pharmaceutical Laboratories and Sun
Pharmaceutical Industries Ltd. for infringement in the wake of Caraco filing ...
Caraco filed a statutory counterclaim in the ongoing infringement action, seeking
an order requiring Novo to “correct” its use code because the patent did not ...
Jun 18, 2013 ... obvious and that the '358 Patent Was Unenforceable Due To Inequitable Conduct.
See Novo Nordisk A/S v. Caraco. Pharm. Labs., 775 F. Supp.
Apr 18, 2012 ... The U.S. Supreme Court, In A Unanimous Decision In Caraco Pharmaceutical
Laboratories, Ltd. v. Novo Nordisk A/S, No. 10-844 (U.S. Apr. 17, ...
Apr 24, 2012 ... Caraco Pharmaceutical Laboratories Caraco filed an ANDA for generic
repaglinide having a Paragraph III certification regarding the '035 ...